Tamoxifen Use and Osteoporotic Fracture Risk: A Population-Based Analysis

Cooke, Andrew; Metge, Colleen; Lix, Lisa M.; Prior, Heather J.; Leslie, William D.

doi:10.1200/jco.2007.15.7123

Cited by 61 publications

(48 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recent Canadian populationbased case-control study compared characteristics of 11,096 patients with osteoporotic fractures with 33,209 matched controls. Results showed that current use of tamoxifen led to a significantly lower overall osteoporotic fracture risk [16].…”

Section: Osteoporosis and Bone Fracturesmentioning

confidence: 95%

Is Endocrine Therapy Really Pleasant? Considerations about the Long-Term Use of Antihormonal Therapy and Its Benefit/Side Effect Ratio

Blaha¹,

Exner²,

Borgo³

et al. 2009

Breast Care

View full text Add to dashboard Cite

Endocrine therapy has become a key part in the adjuvant treatment of hormone responsive breast cancer. The positive effect on relapse risk reduction is well defined, but therapy is not free from bothersome side effects for which estrogen deprivation accounts to a great extent. Since endocrine therapy is usually prescribed for 5 years or longer to optimally display its protective effect, and because physical strain is missing, good tolerability and safety properties are important, particularly in low-risk patients. While tamoxifen has been the standard adjuvant endocrine treatment with well documented efficiency, it is increasingly replaced by third generation aromatase inhibitors due to their better effectiveness and tolerability. Because tamoxifen holds a risk for life-threatening adverse events such as endometrial cancer, pulmonary embolism, and stroke, its recommended duration of therapy is limited to 5 years, also because extension beyond that time did not produce a measurable advantage. While some side effects are present both with tamoxifen and aromatase inhibitors, differences in side effect profiles are well established. Although side effects of aromatase inhibitor-related therapy usually are mild and common to symptoms of menopause, misconception of the symptoms and their mechanism of action, as well as lack of knowledge about how to handle them, can easily lead to dangerous discontinuation of therapy.

show abstract

Section: Osteoporosis and Bone Fracturesmentioning

confidence: 95%

Is Endocrine Therapy Really Pleasant? Considerations about the Long-Term Use of Antihormonal Therapy and Its Benefit/Side Effect Ratio

Blaha¹,

Exner²,

Borgo³

et al. 2009

Breast Care

View full text Add to dashboard Cite

show abstract

“…A retrospective analysis of nursing home patients suggested fewer fractures in patients receiving tamoxifen [41]. A separate retrospective case-controlled study also concluded that tamoxifen was independently associated with fewer hip fractures and combined osteoporotic fractures [42]. In a large prospective clinical trial assessing tamoxifen in primary breast cancer prevention, tamoxifen 20 mg daily was associated with a 32 % relative risk reduction in combined hip, spine, and radius fractures compared to the placebo control group [43].…”

Section: Tamoxifen Effects On Bonementioning

confidence: 97%

Adjuvant Endocrine Therapy and Bone Health in Breast Cancer

Clines

Choksi

Poznak

2015

Curr Osteoporos Rep

View full text Add to dashboard Cite

Breast cancer is one of the most common malignancies of women. The majority of breast cancers express estrogen and/or progesterone receptors, permitting anticancer targeting strategies to reduce estrogen signaling in the cancer cells and thereby lowering the risk of breast cancer recurrence. The development of the selective estrogen receptor modulator (SERM) tamoxifen marked a significant milestone in breast cancer care that transcended older estrogen ablative strategies such as oophorectomy and ovarian irradiation. An unintended benefit of tamoxifen in postmenopausal women was bone density preservation. The third generation of aromatase inhibitors (AIs) have demonstrated superior efficacy to tamoxifen in improving disease-free survival in postmenopausal women. However, the AIs significantly increase bone resorption, reduce bone mineral density, and increase the risk of fracture above that of tamoxifen. As a consequence of this, clinical oncologists have assumed a larger role in the screening and treatment of the skeletal complications of breast cancer therapies. The key features of managing bone health in women with early stage breast cancer receiving adjuvant endocrine therapy are reviewed here.

show abstract

“…Osteoporosis-related fractures, including fractures of the hip, wrist, vertebrae, and humerus were identified from hospital and physician data using case definitions adopted in previous research [26][27][28]. For hip and wrist fractures, we required that the relevant diagnosis code(s) be accompanied by a service code for reduction, fixation or casting, in accordance with previous research, to improve temporal specificity of the fracture date [29,30].…”

Section: Outcome Variablesmentioning

confidence: 99%

Performance of comorbidity measures for predicting outcomes in population-based osteoporosis cohorts

Lix

Quail²,

Teare³

et al. 2011

Osteoporos Int

View full text Add to dashboard Cite

show abstract

Tamoxifen Use and Osteoporotic Fracture Risk: A Population-Based Analysis

Abstract: In a population-based case-control study, current tamoxifen use was associated with a substantial reduction in osteoporotic fractures.

Cited by 61 publications

References 39 publications

Is Endocrine Therapy Really Pleasant? Considerations about the Long-Term Use of Antihormonal Therapy and Its Benefit/Side Effect Ratio

Is Endocrine Therapy Really Pleasant? Considerations about the Long-Term Use of Antihormonal Therapy and Its Benefit/Side Effect Ratio

Adjuvant Endocrine Therapy and Bone Health in Breast Cancer

Performance of comorbidity measures for predicting outcomes in population-based osteoporosis cohorts

Contact Info

Product

Resources

About